期刊文献+

沉淀法制备甲基莲心碱聚乳酸-羟基乙酸共聚物纳米粒 被引量:4

Preparation of neferine-loaded PLGA nanoparticles using precipitation method
原文传递
导出
摘要 目的:制备甲基莲心碱聚乳酸-羟基乙酸共聚物纳米粒(Nef-PLGA-NPs)。方法:以聚乳酸-羟基乙酸共聚物(PLGA)为载体,丙酮为有机溶剂,通过正交试验设计优化沉淀法制备甲基莲心碱PLGA纳米粒的工艺。结果:最佳工艺条件为:PLGA的质量浓度为10 mg.mL-1,Nef的质量浓度为1.0 mg.mL-1,水相与有机相的体积比为20∶1。纳米粒平均包封率为(85.3±0.8)%,平均载药量为(7.75±0.07)%,平均粒径为(82.9±1.2)nm。结论:优化条件下采用沉淀法制备的甲基莲心碱PLGA纳米粒包封率高、载药量大,平均粒径小。 OBJECTIVE To prepare neferine-loaded PLGA nanoparticles (Nef-PLGA NPs). METHODS Nanoparticales were prepared by a precipitation method with poly (lactic-co glycolic) acid (PLGA) as carrier material and acetone as organic solvent, then optimize the formulations by design of orthogonality. RESULTS The best preparation condition: the concentra tion of PLGA was 10 mg·mL^-1 , the concentration of Nef was 1.0mg·mL^-1 , the ratio of water phase and organic phase was 20: 1. The average encapsulation efficiency of resultant nanopartieles was(85.3 ±0. 8) %, the average drug loading was(7. 75 ±0. 07)%, the mean particle size was(82. 9 ±1.2)nm. CONCLUSION Under the optimum conditions, Nef-loaded PI.GA nano-particles prepared by a precipitation method are found to be a high encapsulation efficiency and drug loading, a smaller particle size.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第15期1231-1234,共4页 Chinese Journal of Hospital Pharmacy
基金 国家高新技术研究发展计划(863计划)(编号:2007AA021802)
关键词 甲基莲心碱 纳米粒 沉淀法 正交设计 neferine nanoparticles precipitation orthogonai design
  • 相关文献

参考文献10

  • 1谢纲 曾建国.莲子心的主要成分和药理作用研究进展.湖南中医药大学学报,2007,:384-386.
  • 2秦群,谢兆霞,黄程辉,李新中,万永艳.中药拮新康对K562/A02细胞内阿霉素积聚浓度的影响[J].湖南中医学院学报,2005,25(5):18-20. 被引量:11
  • 3Zhao Libo, Wang Xiaomin, Wu Jianhong, et al. Improved RPHPLC method to determine neferine in dog plasma and its ap- plication to pharmacokinetics[J]. J Ciaromatogra B,20(17,857: 341 346.
  • 4鲁定国,李媛,刘韶,雷鹏,朱诗塔,李新中.影响莲心总碱中甲基莲心碱稳定性因素的试验研究[J].中国中药杂志,2008,33(20):2418-2420. 被引量:3
  • 5Wang M, Thanou M. Targeting nanoparticles to cancer[J]. Pharmaeolog Res, 2010, 62 : 90-99.
  • 6Gupta H,Pharm B, Pharm M, et al. Sparfloxacin-loaded PL GA nanoparticles for sustained ocular drug delivery[J]. Nano medicine,2010,6(2) : 324-333.
  • 7Holgado MA,Arias JL, COzar MJet al. Synthesis of lidocaine loaded PI,GA micropartieles by flow focusing effects on drug loading and release properties[J]. Inter J Pharmaeeut, 2008, 358:27-35.
  • 8Song X,Zhao Y, Hou S,et al. Dual agents loaded PLGA nan- oparticles: systematic study of particle size and drug entrap- ment efficiency[J]. Eur J Pharm Biopharm, 2008, 69: 445- 453.
  • 9王宁,王建新,宋崎,黄大唯,宋英,周小初.正交设计多指标综合评分法优化救心速释片处方[J].中成药,2003,25(3):179-182. 被引量:26
  • 10汪冬庚,刘文英.Doehlert设计矩阵及其在药学中的应用[J].药学进展,2005,29(11):497-502. 被引量:14

二级参考文献37

  • 1曾建伟,吴锦忠,张书娟.莲子心药学研究进展[J].福建中医学院学报,2005,15(S1):40-42. 被引量:20
  • 2雷鹏,刘韶,李新中,徐平声.正交实验优选莲子心提取工艺[J].中国医学工程,2005,13(3):255-256. 被引量:11
  • 3肖希斌,谢兆霞,秦群.甲基莲心碱抑制K562/A02细胞GST-π的表达[J].西安交通大学学报(医学版),2005,26(5):428-430. 被引量:14
  • 4喻晶,胡文淑.甲基莲心碱对兔血小板聚集功能的影响[J].药学学报,1997,32(1):1-4. 被引量:18
  • 5Notarbartolo M, Cervello M, Dusonchet L, et al. Resistance to diverse apoptotic Triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins) [ J]. Cancer Lett, 2002,180( 1 ) :91-101.
  • 6Hamilton G, Theyer G, Baumgartner G. Calcium antagonists as modulators of multidrug resistant tumor cells [ J ]. Wien Med Wochenschr, 1993,143 (19- 20 ) :58-60.
  • 7Box G E P, Wilson K B. On the experimental attainment of optimium conditions[J]. J Roy Star Soc B, 1951,13(2): 1-45.
  • 8Varesio E, Gauvrit J Y, Longeray R, et al. Central composite design in the chiral analysis of amphetamines by capillary electrophoresis[J]. Electrophoresis, 1997, 18(6):931-937.
  • 9Prochazka S, Mulholland M, Lloyd-Jones A. Optimization for the separation of the oligosaccharide, sodium Pentosan Polysulfate by reverse polarity capillary zone electrophoresis using a central composite design [ J]. J Pharmceut Biomed Anal, 2003, 31(1):133-141.
  • 10Box G E P, Behnken D W. Some new three level designs for the study of quantitative variables[J]. Technometrics, 1960,2:455-475.

共引文献54

同被引文献35

  • 1Hu D, Onel E, Singla N, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site[J].Clin Drug Investig, 2013, 33(2): 109-115.
  • 2Moraes CM, de Matos AP, de Lima R, et al. Initial development and characterization of PLGA nanospheres containing ropivacaine[J].Biol Phys, 2007, 33(5-6): 455-461.
  • 3Debbage P. Targeted drugs and nanomedicine: present and future[J].Curr Pharm Des, 2009, 15(2): 153-172.
  • 4de Paula E, MS Cereda C, Fraceto LF, et al. Micro and nanosystems for delivering local anesthetics[J].Drug Deliv, 2012, 9(12): 1505-1526.
  • 5Patricia L, Bret F, Ulery D, et al. Achitosan thermogel for delivery of ropivacain regional musculo skeletal anesthesia[J].Biomaterials, 2013, 34(10): 2539-2546.
  • 6陆彬. 药物新剂型于新技[M]. 北京: 人民卫生出版社, 2005: 217-223.
  • 7Garcia X, Escribano E, Domenech J, et al. In vitro characterization and in vivo analgesicand anti-allodynic activity of PLGA-bupivacaine nanoparticles[J].Nanopart Res, 2011, 13: 2213-2223.
  • 8Carolina M, Moraes E, de Paula E, et al. Physicochemical stability of poly (lactide-co-glycolide) nanocapsules containing the local anesthetic bupivacaine[J].Brazil Chemical Society, 2010, 21(6): 995-1000.
  • 9Zhang H, Lua Y, Zhang G, et al. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic)acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release[J].Int J Pharmac, 2008, 34(351): 244-249.
  • 10Buxton DB. Nanomedicine for the management of lungand blood diseases[J].Nanomedicine, 2009, 4(3): 331-339.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部